129 related articles for article (PubMed ID: 31799839)
1. Structure-Activity Relationships for CYP4B1 Bioactivation of 4-Ipomeanol Congeners: Direct Correlation between Cytotoxicity and Trapped Reactive Intermediates.
Kowalski JP; McDonald MG; Whittington D; Guttman M; Scian M; Girhard M; Hanenberg H; Wiek C; Rettie AE
Chem Res Toxicol; 2019 Dec; 32(12):2488-2498. PubMed ID: 31799839
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate.
Baer BR; Rettie AE; Henne KR
Chem Res Toxicol; 2005 May; 18(5):855-64. PubMed ID: 15892579
[TBL] [Abstract][Full Text] [Related]
3. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol.
Wiek C; Schmidt EM; Roellecke K; Freund M; Nakano M; Kelly EJ; Kaisers W; Yarov-Yarovoy V; Kramm CM; Rettie AE; Hanenberg H
Biochem J; 2015 Jan; 465(1):103-14. PubMed ID: 25247810
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1.
Thesseling FA; Hutter MC; Wiek C; Kowalski JP; Rettie AE; Girhard M
Arch Biochem Biophys; 2020 Jan; 679():108216. PubMed ID: 31801692
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol.
Parkinson OT; Liggitt HD; Rettie AE; Kelly EJ
Toxicol Sci; 2013 Aug; 134(2):243-50. PubMed ID: 23748241
[TBL] [Abstract][Full Text] [Related]
6. Ligand characterization of CYP4B1 isoforms modified for high-level expression in Escherichia coli and HepG2 cells.
Roellecke K; Jäger VD; Gyurov VH; Kowalski JP; Mielke S; Rettie AE; Hanenberg H; Wiek C; Girhard M
Protein Eng Des Sel; 2017 Mar; 30(3):205-216. PubMed ID: 28073960
[TBL] [Abstract][Full Text] [Related]
7. 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1.
Smith PB; Tiano HF; Nesnow S; Boyd MR; Philpot RM; Langenbach R
Biochem Pharmacol; 1995 Nov; 50(10):1567-75. PubMed ID: 7503758
[TBL] [Abstract][Full Text] [Related]
8. Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol.
Teitelbaum AM; McDonald MG; Kowalski JP; Parkinson OT; Scian M; Whittington D; Roellecke K; Hanenberg H; Wiek C; Rettie AE
J Pharmacol Exp Ther; 2019 Feb; 368(2):308-316. PubMed ID: 30409834
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment.
Lim S; Alshagga M; Ong CE; Chieng JY; Pan Y
Hum Exp Toxicol; 2020 Jun; 39(6):785-796. PubMed ID: 32054340
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of furans in vitro: ipomeanine and 4-ipomeanol.
Chen LJ; DeRose EF; Burka LT
Chem Res Toxicol; 2006 Oct; 19(10):1320-9. PubMed ID: 17040101
[TBL] [Abstract][Full Text] [Related]
12. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
[TBL] [Abstract][Full Text] [Related]
13. Prodrug-activating Gene Therapy with Rabbit Cytochrome P450 4B1/4-Ipomeanol or 2-Aminoanthracene System in Glioma Cells.
Jang SJ; Kang JH; Lee TS; Kim SJ; Kim KI; Lee YJ; Cheon GJ; Choi CW; Lim SM
Nucl Med Mol Imaging; 2010 Sep; 44(3):193-8. PubMed ID: 24899949
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on CYP4B1.
Röder A; Hüsken S; Hutter MC; Rettie AE; Hanenberg H; Wiek C; Girhard M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768362
[TBL] [Abstract][Full Text] [Related]
15. Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.
Zheng YM; Henne KR; Charmley P; Kim RB; McCarver DG; Cabacungan ET; Hines RN; Rettie AE
Toxicol Appl Pharmacol; 2003 Jan; 186(2):119-26. PubMed ID: 12639503
[TBL] [Abstract][Full Text] [Related]
16. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
Mohr L; Rainov NG; Mohr UG; Wands JR
Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
[TBL] [Abstract][Full Text] [Related]
17. The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation.
Hsu MH; Baer BR; Rettie AE; Johnson EF
J Biol Chem; 2017 Mar; 292(13):5610-5621. PubMed ID: 28167536
[TBL] [Abstract][Full Text] [Related]
18. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism.
Baer BR; Rettie AE
Drug Metab Rev; 2006; 38(3):451-76. PubMed ID: 16877261
[TBL] [Abstract][Full Text] [Related]
19. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter.
Hsu H; Rainov NG; Quinones A; Eling DJ; Sakamoto KM; Spear MA
Anticancer Res; 2003; 23(3B):2723-8. PubMed ID: 12894565
[TBL] [Abstract][Full Text] [Related]
20. Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons.
Fisher MB; Zheng YM; Rettie AE
Biochem Biophys Res Commun; 1998 Jul; 248(2):352-5. PubMed ID: 9675139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
